IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer

Mostrar otras versiones (1)

CD40 is a central co-stimulatory receptor implicated in the development of productive anti-tumor immune responses across multiple cancers, including bladder cancer. Despite strong preclinical rationale, systemic administration of therapeutic agonistic antibodies targeting the CD40 pathway have demon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Jeffrey L., Smith, Patrick, Angulo-Lozano, Juan, Ranti, Daniel, Bochner, Bernard H., Sfakianos, John P., Horowitz, Amir, Ravetch, Jeffrey V., Knorr, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915460/
https://www.ncbi.nlm.nih.gov/pubmed/36778311
http://dx.doi.org/10.1101/2023.01.30.526266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915460/
https://www.ncbi.nlm.nih.gov/pubmed/36778311
http://dx.doi.org/10.1101/2023.01.30.526266

Ejemplares similares